Skip to main content
search
On-Demand Webinar

Model-Informed Drug Development (MIDD) as a tool to Enhance Asset Value and Address Key Investor Concerns

Model-Informed Drug Development (MIDD) as a tool to Enhance Asset Value and Address Key Investor Concerns

 

Originally aired: US (ET): Thursday, November 6, 11:00am – 11:30am

Now available to watch at your convenience, this on-demand webinar explores how model-informed drug development (MIDD) moves far beyond regulatory submission. In today’s market where long development timelines and investor caution can slow progress, MIDD offers a de-risked, evidence-based approach to attract funding, inform partnerships, and enhance asset valuations.

During this session, our experts from Certara will present:

  • An introduction to MIDD and modelling & simulation (M&S) fundamentals
  • How MIDD supports key milestones such as product assessment, dose justification, target population selection and out-licensing negotiations
  • How small biotech firms and large pharma alike can use MIDD to build investor confidence and improve success rates in drug development and partnering decisions

What You Will Learn

  • How MIDD approaches support the “buyer’s” assessment in in-licensing, partnering or acquisition contexts
  • How MIDD enhances asset value from the “seller’s” perspective – enabling a stronger value story
  • How MIDD acts as a digital twin enabling virtual evaluation of assets and decisions
  • How companies of all sizes, from emerging bio-ventures to established pharma, can leverage MIDD to their benefit

Intended Audience

  • Buyers (venture capital, big pharma, licensing-teams) evaluating in-licensing, acquisitions or partnerships
  • Sellers (bio-ventures, small-to-mid-size pharmaceutical companies) considering out-licensing, partnering or acquisition

Speakers

  • Fran Brown PhD – Senior Vice President, Certara Drug Development Solutions. With 28 years of pharmaceutical development and due diligence experience
  • S. Y. Amy Cheung PhD – Vice President, Certara Drug Development Solutions. Regional lead (EU & APAC) for Quantitative Science Services and global lead for Paediatric & Maternal Health
  • Yu‑Wei (Wayne) Lin PhD – Director of Pharmacometrics, Certara. With 10+ years in PK/PD/TD modelling and MIDD across oncology, immunology, pediatrics and infectious diseases

Access the Webinar

The session is available on-demand, enabling you to view at a time that fits your schedule.

Access this resource